- Home
- WNEB vs INBX Comparison
WNEB vs INBX Comparison
Compare WNEB & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WNEB | INBX |
|---|---|---|
| Founded | 1853 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.2M | 430.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | WNEB | INBX |
|---|---|---|
| Price | $13.25 | $86.53 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 55.8K | ★ 245.4K |
| Earning Date | 01-27-2026 | 11-14-2025 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | ★ 27.15 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $79,080,000.00 | $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | $7.48 | $230.77 |
| P/E Ratio | $20.17 | ★ N/A |
| Revenue Growth | ★ 9.08 | N/A |
| 52 Week Low | $7.63 | $10.81 |
| 52 Week High | $13.95 | $94.47 |
Technical Indicators
Market Signals| Indicator | WNEB | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 69.15 | 58.68 |
| Support Level | $13.20 | $74.80 |
| Resistance Level | $13.49 | $94.47 |
| Average True Range (ATR) | 0.30 | 6.40 |
| MACD | 0.04 | -1.07 |
| Stochastic Oscillator | 58.08 | 59.63 |
Price Performance
Historical ComparisonAbout WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.